Identification of a transcriptionally inactive p53 mutant by functional analysis of separated alleles in yeasts (FASAY) in a child osteosarcoma tumor: A case report

Pediatric Hematology and Oncology

Volumn 21, Issue 4, 2004, Pages 321-328

  Dekairelle, Anne France ^a   Brichard, Bénédicte ^b   Delhez, Huguette ^a   Gala, Jean Luc ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

FASAY; Osteosarcoma; p53; Prognosis

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN;

ALLELE; ARTICLE; BAX GENE; CANCER DIAGNOSIS; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC VALUE; DNA EXTRACTION; DNA SEQUENCE; EXON; FEMALE; FOLLOW UP; FUNCTIONAL ANALYSIS OF SEPARATED ALLELES IN YEAST; GENE; GENE MUTATION; GENETIC ANALYSIS; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LIMB SALVAGE; OSTEOSARCOMA; P21 GENE; POLYMERASE CHAIN REACTION; PROGNOSIS; SACCHAROMYCES CEREVISIAE; SCHOOL CHILD; SEQUENCE ANALYSIS; SOMATIC MUTATION; STOP CODON; SYMPTOM; TIBIA; TUMOR SUPPRESSOR GENE; WOUND INFECTION;

CHILD; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; OSTEOSARCOMA; TIBIA; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042821085     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490440455     Document Type: Article

References (12)

1. Ladanyi M, Gorlick R. Molecular pathology and molecular pharmacology of osteosarcoma [review]. Pedriatr Pathol Mol Med. 2000;19:391-413.
2. Slominski A, Wortsman J, Carlson A, et al. Molecular pathology of soft tissue and bone tumors [review]. Arch Pathol Lab Med. 1999;123:1246-1259.
3. Yokoyama R, SchneiderStork R, Radig K, et al. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Practice. 1998;194:615-621.
4. Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120:91-98.
5. Park YB, Kim HS, Oh JH, et al. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop. 2001;24:307-310.
6. Meinhold-Heerlein I, Ninci E, Ikenberg H, et al. Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology. 2001;60:176-188.
7. Camplejohn RS, Rutherford J. p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumors. Cell Prolif. 2001;34:1-14.
8. Flaman JM, Robert V, Lenglet S, et al. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene. 1998;16:1369-1372.
9. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human p53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer. 1992;5:89-90.
10. Hogg A, Onadim Z, Baird PN, et al. Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing. Oncogene. 1992;7:1445-1451.
11. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and melastatic osteosarcoma. Cancer. 2001;92:2181-2189.
12. Smith Sorensen B, Gebhardt MC, Kloen P, et al. Screening for TP 53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat. 1993;2:274-285.